/
Cardiovascular
Hypertrophic Cardiomyopathy
9
Pipeline Programs↗
38
Active Trials↗
8
Companies Involved↗
Hypertrophic Cardiomyopathy is an early-stage landscape with 9 programs across 8 companies. The most active players are Bristol-Myers Squibb, Edgewise Therapeutics, Inc., Imbria Pharmaceuticals, Inc.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 23
Phase 34
Approved
No programs
Analysis
Trial Status
78
clinical trials
Completed27 · 35%
Recruiting16 · 21%
Active, not recruiting15 · 19%
Not yet recruiting6 · 8%
Terminated5 · 6%
Unknown status5 · 6%
Other4 · 5%
Clinical Trials
Trial Activity
78 trials
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)